oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2020 ( 4 )

2019 ( 207 )

2018 ( 241 )

2017 ( 242 )

Custom range...

Search Results: 1 - 10 of 144392 matches for " Waeber B "
All listed articles are free for downloading (OA Articles)
Page 1 /144392
Display every page Item
Critical review of cancer risk associated with angiotensin receptor blocker therapy
Wuerzner G, Burnier M, Waeber B
Vascular Health and Risk Management , 2011, DOI: http://dx.doi.org/10.2147/VHRM.S13552
Abstract: itical review of cancer risk associated with angiotensin receptor blocker therapy Review (2444) Total Article Views Authors: Wuerzner G, Burnier M, Waeber B Published Date December 2011 Volume 2011:7 Pages 741 - 747 DOI: http://dx.doi.org/10.2147/VHRM.S13552 Grégoire Wuerzner1,3, Michel Burnier1, Bernard Waeber2,3 1Service of Nephrology and Hypertension Consultation, Centre Hospitalier Universitaire Vaudois, 2Division of Clinical Pathophysiology, Centre Hospitalier Universitaire Vaudois, 3Clinical Research Centre, Unil/Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland Abstract: The role of drugs in new cancer occurrence and cancer-related death is a major concern. Recently, a meta-analysis raised the possibility that angiotensin receptor blockers (ARBs) might have an adverse effect on patients. This generated a significant debate until the publication of two further meta-analyses, neither of which demonstrated an increased risk of new cancer occurrence or cancer-related death with the use of ARBs in patients with hypertension, heart failure, and/or nephropathy. This illustrates that the results of meta-analyses should be interpreted cautiously and critically as bias, such as selection bias, might lead to erroneous conclusions. Overall, the bulk of evidence today indicates that ARBs are not associated with increased cancer risk.
Critical review of cancer risk associated with angiotensin receptor blocker therapy
Wuerzner G,Burnier M,Waeber B
Vascular Health and Risk Management , 2011,
Abstract: Grégoire Wuerzner1,3, Michel Burnier1, Bernard Waeber2,31Service of Nephrology and Hypertension Consultation, Centre Hospitalier Universitaire Vaudois, 2Division of Clinical Pathophysiology, Centre Hospitalier Universitaire Vaudois, 3Clinical Research Centre, Unil/Centre Hospitalier Universitaire Vaudois, Lausanne, SwitzerlandAbstract: The role of drugs in new cancer occurrence and cancer-related death is a major concern. Recently, a meta-analysis raised the possibility that angiotensin receptor blockers (ARBs) might have an adverse effect on patients. This generated a significant debate until the publication of two further meta-analyses, neither of which demonstrated an increased risk of new cancer occurrence or cancer-related death with the use of ARBs in patients with hypertension, heart failure, and/or nephropathy. This illustrates that the results of meta-analyses should be interpreted cautiously and critically as bias, such as selection bias, might lead to erroneous conclusions. Overall, the bulk of evidence today indicates that ARBs are not associated with increased cancer risk.Keywords: hypertension, cancer, angiotensin receptor blocker, meta-analyses
Short communication on the Alaotra gentle lemur: Population estimation and subsequent implications
Fidimalala B. Ralainasolo,Patrick O. Waeber,Jonah Ratsimbazafy,Joanna Durbin
Madagascar Conservation & Development , 2006,
Abstract: Durrell Wildlife Conservation Trust (DWCT) has conducted since 1994 several census’ on the population of the Alaotran gentle lemur to observe the development of the population in time and space.
Biodiversity offsetting – en vogue in Madagascar?
PO Waeber
Madagascar Conservation & Development , 2012,
Abstract: Editorial - no abstract
Roots & Shoots: A model for active environmental protection
PO Waeber
Madagascar Conservation & Development , 2006,
Abstract: Madagascar is facing severe environmental problems. One approach to engage possible future stakeholders and to raise awareness for environmental concerns is the Roots & Shoots program. On the following the program and its philosophy are presented.
Biodiversity offsetting – en vogue in Madagascar?
Patrick O. Waeber
Madagascar Conservation & Development , 2012,
Abstract:
Selectivity and Specificity of Sphingosine-1-Phosphate Receptor Ligands: Caveats and Critical Thinking in Characterizing Receptor-Mediated Effects
Salvatore Salomone,Christian Waeber
Frontiers in Pharmacology , 2011, DOI: 10.3389/fphar.2011.00009
Abstract: Receptors for sphingosine-1-phosphate (S1P) have been identified only recently. Their medicinal chemistry is therefore still in its infancy, and few selective agonists or antagonists are available. Furthermore, the selectivity of S1P receptor agonists or antagonists is not well established. JTE-013 and BML-241 (also known as CAY10444), used extensively as specific S1P2 and S1P3 receptors antagonists respectively, are cases in point. When analyzing S1P-induced vasoconstriction in mouse basilar artery, we observed that JTE-013 inhibited not only the effect of S1P, but also the effect of U46619, endothelin-1 or high KCl; JTE-013 strongly inhibited responses to S1P in S1P2 receptor knockout mice. Similarly, BML-241 has been shown to inhibit increases in intracellular Ca2+ concentration via P2 receptor or α1A-adrenoceptor stimulation and α1A-adrenoceptor-mediated contraction of rat mesenteric artery, while it did not affect S1P3-mediated decrease of forskolin-induced cyclic AMP accumulation. Another putative S1P1/3 receptor antagonist, VPC23019, does not inhibit S1P3-mediated vasoconstriction. With these examples in mind, we discuss caveats about relying on available pharmacological tools to characterize receptor subtypes.
Amlodipine and valsartan as components of a rational and effective fixed-dose combination
Bernard Waeber, Luis M Ruilope
Vascular Health and Risk Management , 2009, DOI: http://dx.doi.org/10.2147/VHRM.S3134
Abstract: mlodipine and valsartan as components of a rational and effective fixed-dose combination Review (8605) Total Article Views Authors: Bernard Waeber, Luis M Ruilope Published Date March 2009 Volume 2009:5 Pages 165 - 174 DOI: http://dx.doi.org/10.2147/VHRM.S3134 Bernard Waeber1, Luis M Ruilope2 1Division of Clinical Pathophysiology, University Hospital, Faculty of Biology and Medicine, University of Lausanne, Switzerland; 2Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain Abstract: Pharmacological treatment of hypertension is effective in preventing cardiovascular and renal complications. Calcium antagonists and blockers of the renin-angiotensin system are widely used today to initiate antihypertensive therapy but, when given as monotherapy, do not suffice in most patients to normalize blood pressure. Combining the two types of agents considerably increases the antihypertensive efficacy, but not at the expense of a deterioration of tolerability. This is exemplified by the experience accumulated with the recently developed fixed dose combination containing the AT1-receptor blocker valsartan (160 mg) and the dihydropyridine amlodipine (5 or 10 mg). In a randomized trial, an 8-week treatment normalized blood pressure (<140/90 mmHg) within 8 weeks in a large fraction of hypertensive patients (78.4% and 85.2% using the 5/160 [n = 371] and 10/160 mg [n = 377] dosage, respectively). Like all AT1-receptor blockers valsartan has a placebo-like tolerability. Valsartan prevents to a large extent the occurrence amlodipine-induced peripheral edema. Both amlodipine and valsartan have beneficial effects on cardiovascular morbidity and mortality, as well as protective effects on renal function. The co-administration of these two agents is therefore very attractive, as it enables a rapid and sustained blood pressure control in hypertensive patients. The availability of a fixed-dose combination based on amlodipine and valsartan is expected therefore to facilitate the management of hypertension, to improve long-term adherence with antihypertensive therapy and, ultimately, to have a positive impact on cardiovascular and renal outcomes.
Radio broadcasting for sustainable development in southern Madagascar
Patrick O. Waeber,Yvonne Orengo
Madagascar Conservation & Development , 2008,
Abstract: The Millennium Development Goals have been written into the Madagascar Road Map (2007 - 2012) in order to improve the Malagasy social, economic and environmental situation. The Andrew Lees Trust Radio Broadcasting Project in southern Madagascar has been set up to alleviate poverty and, through a recent DFID (Department for International Development) funded evaluation study, has demonstrated its contribution and work towards the United Nations targets set for 2015. This article draws on the DFID study, “The Contribution of Radio to Millennium Development Goals in Southern Madagascar“, to illustrate the project’s success in approaching the main goals of poverty alleviation and education. Radio is a cost effective, non - formal learning medium, which can reach across vast geographic distances to communities in the most remote and isolated regions, and can deliver vital development information to all members of the community irrespective of age, gender, or beliefs. This article reinforces the assertion that radio can act as a vital tool in reaching Millennium Development Goals in Madagascar and beyond. RéSUMé. Les Objectifs de Développement du Millénium ont été inscrits sur la Feuille de Route de Madagascar afin d’améliorer la situation sociale, économique et environnementale à Madagascar. Le projet d’émission radiophonique de l’ONG Andrew Lees Trust a été élaboré pour lutter contre la pauvreté et s’est avéré capable d’apporter des éléments décisifs pour atteindre les objectifs fixés par les Nations Unies pour 2015 selon une étude récente du Département pour le Développement International (DFID). Cet article s’inspire des études du DFID “The Contribution of Radio to Millennium Development Goals in Southern Madagascar” pour illustrer en partie la réussite du projet quant à la réalisation des principaux objectifs que sont l’éducation et la diminution de la pauvreté. La radio est un moyen de communication peu onéreux, qui ne nécessite aucune formation particulière mais qui a la capacité de couvrir de vastes zones géographiques pour atteindre les communautés les plus isolées et les plus reculées afin qu’elles aient accès, quel que soit leur age, sexe, et croyance, à des informations essentielles portant sur le développement. Cet article confirme l’importance vitale de la radio pour atteindre les Objectifs de Développement du Millénium à Madagascar.
Amlodipine and valsartan as components of a rational and effective fixed-dose combination
Bernard Waeber,Luis M Ruilope
Vascular Health and Risk Management , 2009,
Abstract: Bernard Waeber1, Luis M Ruilope21Division of Clinical Pathophysiology, University Hospital, Faculty of Biology and Medicine, University of Lausanne, Switzerland; 2Hypertension Unit, Hospital 12 de Octubre, Madrid, SpainAbstract: Pharmacological treatment of hypertension is effective in preventing cardiovascular and renal complications. Calcium antagonists and blockers of the renin-angiotensin system are widely used today to initiate antihypertensive therapy but, when given as monotherapy, do not suffice in most patients to normalize blood pressure. Combining the two types of agents considerably increases the antihypertensive efficacy, but not at the expense of a deterioration of tolerability. This is exemplified by the experience accumulated with the recently developed fixed dose combination containing the AT1-receptor blocker valsartan (160 mg) and the dihydropyridine amlodipine (5 or 10 mg). In a randomized trial, an 8-week treatment normalized blood pressure (<140/90 mmHg) within 8 weeks in a large fraction of hypertensive patients (78.4% and 85.2% using the 5/160 [n = 371] and 10/160 mg [n = 377] dosage, respectively). Like all AT1-receptor blockers valsartan has a placebo-like tolerability. Valsartan prevents to a large extent the occurrence amlodipine-induced peripheral edema. Both amlodipine and valsartan have beneficial effects on cardiovascular morbidity and mortality, as well as protective effects on renal function. The co-administration of these two agents is therefore very attractive, as it enables a rapid and sustained blood pressure control in hypertensive patients. The availability of a fixed-dose combination based on amlodipine and valsartan is expected therefore to facilitate the management of hypertension, to improve long-term adherence with antihypertensive therapy and, ultimately, to have a positive impact on cardiovascular and renal outcomes.Keywords: antihypertensive therapy, fixed-dose combination, calcium antagonists, angiotensin receptor blockers, blood pressure control, tolerability
Page 1 /144392
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.